Products

Oncology Injection Oncology Injection

Name Active Ingredient / Formulation Strength Indication Characteristics
Genexol® PM Inj.
Genexol® PM Inj.
Paclitaxel/Lyo. 30mg,
100mg
Breast cancer,
NSCLC,
Ovarian cancer
  • Cremophor-free
  • Higher MTD
  • No alcohol intoxication
Nanoxel® M Inj.
Nanoxel® M Inj.
Docetaxel/Lyo. 20mg,
80mg
Breast cancer,
NSCLC,
Esophageal cancer,
Ovarian cancer,
H&N cancer,
Gastric cancer,
Prostate cancer
  • Polysorbate 80-free
  • No alcohol intoxication
Genexol® Inj.
Genexol® Inj.
Paclitaxel/Liq. 30mg,
100mg,
300mg
Breast cancer,
NSCLC,
Ovarian cancer
  • Cremophor-containing formulation
Docetaxel Inj.
Docetaxel Inj.
Docetaxel/Liq. 20mg,
80mg,
140mg,
160mg
Breast cancer,
NSCLC,
Esophageal cancer,
Ovarian cancer,
H&N cancer,
Gastric cancer,
Prostate cancer
  • 1-vial liq. Inj.
  • Ready to use
Zolenic® Inj.
Zolenic® Inj.
Zoledronic acid/Liq. 4mg Bone complications of cancer
  • Same efficacy with the Original product
Nexatin® Inj.
Nexatin® Inj.
Oxaliplatin/Liq. 50mg,
100mg,
200mg
Colorectal cancer,
Gastric cancer
  • Same efficacy with the Original product
Pemed® Inj.
Pemed® Inj.
Pemetrexed/Lyo. & Liq. 100mg,
500mg,
1,000mg
NSCLC
  • RTU & Lyo
  • Cold & Room
Crabcitabin® Inj.
Gemcitabine/Liq. 200mg,
1,000mg
Pancreas, Lung, Ovary, and Breast
  • Cold storage
Protezomib® Inj.
Protezomib® Inj.
Bortezomib/Lyo. 3.5mg,
2.5mg
Mantle cell lymphoma, Multiple Myeloma
  • Same efficacy with the Original product
Palonosetron Inj.
Palonosetron/Liq 1.5mg,
5mg
Antiemetics
  • 5-HT3 antagonist
  • No EDTA
  • No patent infringement
  • Same efficacy with the Original product
Emestop® Inj.
Ramosetron/Liq 0.1mg Antiemetics
  • Same efficacy with the Original product
Emestop® FDT
Ramosetron/Tablet 0.3mg Antiemetics
  • Same efficacy with the Original product